In indirect comparisons of safety analyses, there were no discernible differences between PD‐L1 inhibitors + chemotherapy relative to PD‐1 inhibitors + chemotherapy in relation to any grade of AE, grade ≥ 3 AE, in relation to any grade of neutropenia, or grade ≥ 3 neutropenia (Figure 4). This evidence concerns the gene PDCD1 and neutropenia.